These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
322 related articles for article (PubMed ID: 20819220)
1. Randomized phase II study evaluating a carbon ion boost applied after combined radiochemotherapy with temozolomide versus a proton boost after radiochemotherapy with temozolomide in patients with primary glioblastoma: the CLEOPATRA trial. Combs SE; Kieser M; Rieken S; Habermehl D; Jäkel O; Haberer T; Nikoghosyan A; Haselmann R; Unterberg A; Wick W; Debus J BMC Cancer; 2010 Sep; 10():478. PubMed ID: 20819220 [TBL] [Abstract][Full Text] [Related]
2. Randomised phase I/II study to evaluate carbon ion radiotherapy versus fractionated stereotactic radiotherapy in patients with recurrent or progressive gliomas: the CINDERELLA trial. Combs SE; Burkholder I; Edler L; Rieken S; Habermehl D; Jäkel O; Haberer T; Haselmann R; Unterberg A; Wick W; Debus J BMC Cancer; 2010 Oct; 10():533. PubMed ID: 20925951 [TBL] [Abstract][Full Text] [Related]
3. Comparison of carbon ion radiotherapy to photon radiation alone or in combination with temozolomide in patients with high-grade gliomas: explorative hypothesis-generating retrospective analysis. Combs SE; Bruckner T; Mizoe JE; Kamada T; Tsujii H; Kieser M; Debus J Radiother Oncol; 2013 Jul; 108(1):132-5. PubMed ID: 23932193 [TBL] [Abstract][Full Text] [Related]
4. Dose-painting multicenter phase III trial in newly diagnosed glioblastoma: the SPECTRO-GLIO trial comparing arm A standard radiochemotherapy to arm B radiochemotherapy with simultaneous integrated boost guided by MR spectroscopic imaging. Laprie A; Ken S; Filleron T; Lubrano V; Vieillevigne L; Tensaouti F; Catalaa I; Boetto S; Khalifa J; Attal J; Peyraga G; Gomez-Roca C; Uro-Coste E; Noel G; Truc G; Sunyach MP; Magné N; Charissoux M; Supiot S; Bernier V; Mounier M; Poublanc M; Fabre A; Delord JP; Cohen-Jonathan Moyal E BMC Cancer; 2019 Feb; 19(1):167. PubMed ID: 30791889 [TBL] [Abstract][Full Text] [Related]
5. Carbon ion radiotherapy boost in the treatment of glioblastoma: a randomized phase I/III clinical trial. Kong L; Gao J; Hu J; Lu R; Yang J; Qiu X; Hu W; Lu JJ Cancer Commun (Lond); 2019 Feb; 39(1):5. PubMed ID: 30786916 [TBL] [Abstract][Full Text] [Related]
6. Phase I/II trial evaluating carbon ion radiotherapy for the treatment of recurrent rectal cancer: the PANDORA-01 trial. Combs SE; Kieser M; Habermehl D; Weitz J; Jäger D; Fossati P; Orrechia R; Engenhart-Cabillic R; Pötter R; Dosanjh M; Jäkel O; Büchler MW; Debus J BMC Cancer; 2012 Apr; 12():137. PubMed ID: 22472035 [TBL] [Abstract][Full Text] [Related]
8. A randomized phase III study of short-course radiotherapy combined with Temozolomide in elderly patients with newly diagnosed glioblastoma; Japan clinical oncology group study JCOG1910 (AgedGlio-PIII). Arakawa Y; Sasaki K; Mineharu Y; Uto M; Mizowaki T; Mizusawa J; Sekino Y; Ono T; Aoyama H; Satomi K; Ichimura K; Kinoshita M; Ohno M; Ito Y; Nishikawa R; Fukuda H; Nishimura Y; Narita Y; BMC Cancer; 2021 Oct; 21(1):1105. PubMed ID: 34654402 [TBL] [Abstract][Full Text] [Related]
9. Efficacy of moderately hypofractionated simultaneous integrated boost intensity-modulated radiotherapy combined with temozolomide for the postoperative treatment of glioblastoma multiforme: a single-institution experience. Zhong L; Chen L; Lv S; Li Q; Chen G; Luo W; Zhou P; Li G Radiat Oncol; 2019 Jun; 14(1):104. PubMed ID: 31196126 [TBL] [Abstract][Full Text] [Related]
10. Hypofractionated intensity-modulated radiotherapy using simultaneous integrated boost technique with concurrent and adjuvant temozolomide for glioblastoma. Yoon SM; Kim JH; Kim SJ; Khang SK; Shin SS; Cho YH; Jwa E; Park JH; Ahn SD Tumori; 2013; 99(4):480-7. PubMed ID: 24326836 [TBL] [Abstract][Full Text] [Related]
11. Radiotherapy plus temozolomide in elderly patients with glioblastoma: a "real-life" report. Biau J; Chautard E; De Schlichting E; Dupic G; Pereira B; Fogli A; Müller-Barthélémy M; Dalloz P; Khalil T; Dillies AF; Durando X; Godfraind C; Verrelle P Radiat Oncol; 2017 Dec; 12(1):197. PubMed ID: 29212499 [TBL] [Abstract][Full Text] [Related]
12. Randomized study of postoperative radiotherapy and simultaneous temozolomide without adjuvant chemotherapy for glioblastoma. Kocher M; Frommolt P; Borberg SK; Rühl U; Steingräber M; Niewald M; Staar S; Stuschke M; Becker G; Fischedick AR; Herfarth K; Grauthoff H; Müller RP Strahlenther Onkol; 2008 Nov; 184(11):572-9. PubMed ID: 19016015 [TBL] [Abstract][Full Text] [Related]
13. Hypofractionated intensity modulated radiotherapy with temozolomide in newly diagnosed glioblastoma multiforme. Ammirati M; Chotai S; Newton H; Lamki T; Wei L; Grecula J J Clin Neurosci; 2014 Apr; 21(4):633-7. PubMed ID: 24380758 [TBL] [Abstract][Full Text] [Related]
14. Postoperative neoadjuvant temozolomide before radiotherapy versus standard radiotherapy in patients 60 years or younger with anaplastic astrocytoma or glioblastoma: a randomized trial. Malmström A; Poulsen HS; Grønberg BH; Stragliotto G; Hansen S; Asklund T; Holmlund B; Łysiak M; Dowsett J; Kristensen BW; Söderkvist P; Rosell J; Henriksson R; Acta Oncol; 2017 Dec; 56(12):1776-1785. PubMed ID: 28675067 [TBL] [Abstract][Full Text] [Related]
15. Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme. Reddy K; Damek D; Gaspar LE; Ney D; Waziri A; Lillehei K; Stuhr K; Kavanagh BD; Chen C Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):655-60. PubMed ID: 22483738 [TBL] [Abstract][Full Text] [Related]
16. First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience. Bock HC; Puchner MJ; Lohmann F; Schütze M; Koll S; Ketter R; Buchalla R; Rainov N; Kantelhardt SR; Rohde V; Giese A Neurosurg Rev; 2010 Oct; 33(4):441-9. PubMed ID: 20706757 [TBL] [Abstract][Full Text] [Related]
17. Accelerated hyperfractionated radiochemotherapy with temozolomide is equivalent to normofractionated radiochemotherapy in a retrospective analysis of patients with glioblastoma. Lewitzki V; Klement RJ; Kosmala R; Lisowski D; Flentje M; Polat B Radiat Oncol; 2019 Dec; 14(1):227. PubMed ID: 31831026 [TBL] [Abstract][Full Text] [Related]
18. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial. Lanzetta G; Campanella C; Rozzi A; Nappa M; Costa A; Fedele F; Innocenzi G; Gagliardi FM; Salvati M; Minniti G; Frati A; Frati L; Vecchione A Anticancer Res; 2003; 23(6D):5159-64. PubMed ID: 14981983 [TBL] [Abstract][Full Text] [Related]
19. Initial experience with scalp sparing radiation with concurrent temozolomide and tumor treatment fields (SPARE) for patients with newly diagnosed glioblastoma. Song A; Bar-Ad V; Martinez N; Glass J; Andrews DW; Judy K; Evans JJ; Farrell CJ; Werner-Wasik M; Chervoneva I; Ly M; Palmer JD; Liu H; Shi W J Neurooncol; 2020 May; 147(3):653-661. PubMed ID: 32206976 [TBL] [Abstract][Full Text] [Related]
20. Can elderly patients with newly diagnosed glioblastoma be enrolled in radiochemotherapy trials? Fiorentino A; Balducci M; De Bonis P; Chiesa S; De Filippo L; Mangiola A; De Rose F; Autorino R; Rinaldi C; Fersino S; Diletto B; Matteucci P; Ciurlia E; Fusco V; Anile C; Valentini V Am J Clin Oncol; 2015 Feb; 38(1):23-7. PubMed ID: 23388566 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]